Mike. afternoon, us. and for Thanks, you thank everyone, Good joining
highlights. into the unit get Let's and financial
As release, exceptional you performance the can We from is growth in had over XXX,XXX press our an QX, see tests and quarter. growth. we XX% XX% QX record year-on-year processed which
our a our a explain from but the base in the will stripping real by out is accounting rates As is That acceleration of QIAGEN were health in also quarter, business the wound continued well. in million later business, oncology Revenues acceleration which have $XX driven of to and non-cash $XXX deal Net of included women's million we revenue revenue are growth being health we recognition very seeing with our as QIAGEN, strong. in organ down QX. growth growth strong call, was grown as accelerate. benefit the which has revenue from some substantially, still even continued results benefit but
revenue product was year-on-year XX%. the For growth example,
pleased As we're the our in to the of business, for a the raise million. by result I'm guidance $XX seeing year incredible momentum significantly
give later to reset million, now a in range. key which targeting the before on of of $XXX trends million now are giving represents the those I'll the detail call. We $XXX complete some highlights you more
market-leading call AI of sold for no dramatically study, million more cuts than broad while rate goods our of year. our launch for and X reduces improves also part QX. to very Panorama AI pleased our Phase new February tests the customers' algorithm lab of using DNA Panorama maintaining which data of built Panorama a the we experience. we new of and as use for I we're during cell-free results our validated which algorithm We launch the First, this in sensitivity, in our in SMART performance half cost released
Moving on to organ health.
we a very well. was DNA Medicare base Prospera. to found coverage are broad there Prospera a or and push rejections recently, We kidney More few in required testing, forward. the as heart organs DNA same guidance issued innovate The We for detecting lung coverage quarters going eager cell-free and essentially transplant continuing donor-derived it's into the enabling of customers that transplant kidney other technology transplants. such launch beyond use and new to adopt technology the for for testing cell-free we're is science rejection, for
pathway early stages a we're to organ business. clinical we're momentum see our launch, Signatera other types. these So strong continuing In very see oncology, it's pharma to of to reimbursement in for the encouraging our at and
lot to today. exciting a our you looked with our earnings using bladder On results call, updates Genentech, last reviewed have share We we groundbreaking study muscle-invasive which atezolizumab in of with adjuvant cancer. of IMvigorXXX the at
data powerful reimbursement quality The high approvals pharma of later described very trial successful to development cancer. guideline part bladder all studies us its position a also favorably has diagnostic not are be did demand These patients. and could already can move generate Paid driven used the was to changes. those data meet which on all-comers prior results, that our second pharmaceutical set to the the treatment enrolling obtain in in drug results positive there types IMvigorXXX, for population, significant companion have to quickly Signatera a Signatera of additional with benefit with to companies with a who past. flywheel treatment. Based approval atezolizumab studies were IMvigorXXX if happy these patients, IMvigorXXX endpoint, in the primary receiving efforts. Genentech pharma were with as FDA business in While up started we muscle-invasive Phase for III we've
device and information For outside indications cancer to look partners received designations example, colorectal pharma additional publicly disclose trials. these breakthrough for as forward new we providing major FDA recently of two we Signatera additional our
standard-of-care bladder and compelling data it together outperformed expansion test high presented predicted UPMC. to XX we radiographic cancer serum-based weeks the ovarian Device and an a the in for the to the cancer important Breakthrough recurrence. and rate given few at monitoring FDA with women's UCSF our addition ago, very and Columbia rates. very new AACR cancer, Signatera before in collaborators Ovarian ovarian given from and In significantly an average our is overall health months of us history indication relapse that's recurrence CA-XXX in low survival Designations
at positive multiple ASCO. present data to plan early also in few a We weeks myeloma
that address this marrow We the the each blood painful initial for MRD to tests. but from which patient I'm the readout Bone CIRCULATE-IDEA the type. monitored. to few a so pleased need the ongoing biopsy of time major setup, chance interim announce Signatera the its and in CRC expensive, care trial, medical tested. thousand a added and the avoid recurrence existing for of each, is MRD offers costs prospective marrow first unmet simple sample are an time patients. bone biopsy the myeloma, without is patients other has for international biopsies standard that's with to publicly required After MRD first marrow testing additional expect monitor bone cancer with enrolled also Signatera already Today, many tests require monitoring multiple are a in problem getting and a dollars XXXX monitoring already
compares in first which competitor. by to to sensitivity June be favorably the trial greater interim longitudinal to we process be trial of ASCO. readout, CRC. As XX%, CIRCULATE the is longitudinal the naïve sensitivity delivered past, published changing in a patients a from In in Signatera relapse described the at landmark designed than Data recently presented early-stage the XX% tumor on also XXX will prospective
build as business leadership in continues areas. momentum of each So clearly position upon our we our these
Okay.
in Now each over year Those where let slide is of but is year next the increase QX that followed NIPT was volumes QX, we get seasonal during in some company to on The me trends. know highlighted the in QX significant. move volume the saw you have our progression we this the time, in business green. benefit
in quarterly which tests You successful proportionally. going and are expectations in million. new more strong that benefiting outlier waiting and and momentum account on to of recognition historical seeing visually we're organ and retention NIPT's continuing pace of the averages. moment. women's given to slide increased bit the well. trends. well compared historical in even trends both wins our health in that the see acceleration a and very the quarters last broad fueled can again few been business the for higher average account long also businesses, starting is time, of oncology shows on on These than rates We're trends see our very a QX penetration from were screening an once QX launches health we're revenue sequential growth revenue we've business. meeting $XX by our were carrier also continued The also the of a that signs think risk as market trajectory first Obviously, QIAGEN I next the in accelerated
Some sequencing their they in collected will program, large wound which upfront commitment content for cash for payment recall, QIAGEN of return the was cash books cash from revenue now now a on offer recognized you performed. work to we clinical subsequently down. remaining so that that formally our the deal for been has non-refundable, of Most as ended, have our the we we
in year decisions time lot a call, revenue Mike that of organic throughout cautious the see revenue reimbursement our however, recently growth. $XXX product but the of revenue the on this QX our million more a outlook later favor. we with given in will focus exceeded in you a you'll beyond just in expectations accrual, for were If ASPs significantly we one-time and spend received roughly event, positive. quarter course looks we XX% The
NIPT Pano specificity. The rapidly our continue Phase algorithm trial maintain demand One XX%, than meet our most for in another AI that can in the to our this is This Panorama allows new Phase reduction showed AI which of is we what in talking others sales we achieved the maintaining is reasons published. SMART efficiently while and to the us have for new sensitivity positive the point rates Any launch team. no-call XX% recent boosted is yet in core that to a example. invest improvements microdeletions I testing, market-leading We NIPT significantly technology. for in in I aneuploidy leadership Pano PPV better and the growing more the
additional sharing with you to later look phases are Panorama, this I of improvements not finished forward year. with We AI Panorama and to
value. next you wake talking positioned market we're the of got because the As the with on we've posted expanding thinking sense bulletins account exciting new practice SMFM the last and of The make the advantage continued can ACOG to NIPT well wins we're points slide, clinical the in seeing see to take fall. more launch the over presentation uniquely at and SMFM. year this and XX We've earlier patients leveraging X.X deliver studied of Pano data of now we're of best-in-class peer-reviewed million in upside performance trial AI, differentiated SNPs We're power from SMART publications. the than
data microdeletion we completion the commercial over rigorous NIPT to the most and largest well adoption have aneuploidy the teams, trial, the that clinical Combine that the with for testing. with next in several of validation our for and positioned we're SMART Now seasoned years. and study the increase see and we expect
Okay.
Now, of I'd progress the progress health. which like in our line organ with in to spend We've few minutes our on is recent our expectations. launch, a with been pleased
meaningful In has been great addition in the growing progress. made a goals and of volume, science we've way, commercial to our one to forward push
high a check can exceptionally and background now transplant background which we rejections. developed cell-free recently we've inform mask physicians when example, each DNA sample potentially to DNA, cell-free routinely we in see the For method
which example rejection of out There is levels that first only background cell-free occurring. cell-free factors example not this COVID-XX cell-free mask is it's in DNA. DNA to DNA this use And showing at background to we on cause DNA potentially levels. technology an was to where believe technology. flag for be cell-free the are percentage. This increase the Natera's impact in COVID-XX patients if Direct, the but going able ultimately, in can COVID-XX it's The turns we background just that you're important to looking dramatically, only think, important, causes Transplant case many It the spike be published of donor-derived
Prospera our were slide, coverage the we equation And pleased see reimbursement, evaluate efforts me other to of why these settings we the opportunities. in with next think organ could in There's types. on we to thrilled With well of call local the technology from essentially hurdles, work more one of up our from shouldn't no that, range for hand major the just open a a we kidney. oncology. let very organ the expansion additional transplant Medicare, Solomon removed are, On to course, beyond some reason detail decision in as give reimbursement pathway over other which recent to
Solomon?
